Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Orig3n

Orig3n
2014 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
Series B LATEST DEAL TYPE
$50M LATEST DEAL AMOUNT
12 INVESTORS
Description

Provider of a DNA test kits intended to treat rare genetically inherited diseases. The company's DNS tests leverage biological science and technology to provide people with access to information about their genes to make proactive and personalized choices that may impact their well-being.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 27 Drydock Avenue
  • 3rd Floor
  • Boston, MA 02210
  • United States

+1 (800) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Orig3n’s full profile, request a free trial.

Orig3n Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series B) 11-Jul-2018 $50M 000.00 00000 Completed Generating Revenue
3. Early Stage VC (Series A2) 27-Jun-2017 0000 000.00 0000 Completed Generating Revenue
2. Early Stage VC (Series A) 16-Dec-2015 $12.5M $15.6M 0000 Completed Startup
1. Early Stage VC (Series 1) 05-Feb-2015 $3.14M $3.14M 00.000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Orig3n Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series A2 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series A 11,372,211 $0.000100 6% $1.1 $1.1 1x $1.1 13.49%
Series 1 7,498,225 $0.000100 6% $0.42 $0.42 1x $0.42 8.89%
To view this company’s complete Cap Table, request access »

Orig3n Competitors (46)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Verge Genomics Venture Capital-Backed San Francisco, CA 00 000.00 00000000000 000.00
000000 Venture Capital-Backed Cambridge, MA 00.00 00000000000 00.00
000000000 00000000 Venture Capital-Backed Salt Lake City, UT 000 00000 000000000 00000
000000000000 Venture Capital-Backed Houston, TX 000.00 00000000000 000.00
00000000 Venture Capital-Backed San Francisco, CA 00 000.00 00000000000 000.00
To view this company’s complete list of competitors, request access »

Orig3n Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000000 000000 22-Nov-2017 000000000000000000 Diagnostic Equipment
To view this company’s complete investment and acquisition history, request access »

Orig3n Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
Haitong International Securities Group Other Minority 000 0000 000000 0
MMIC Investment Venture Capital Minority 000 0000 000000 0
Vectr Ventures Venture Capital Minority 000 0000 000000 0
Spectrum Health Ventures Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »

Orig3n Executive Team (7)

Name Title Board
Seat
Contact
Info
Robin Smith Co-Founder & Chief Executive Officer
Kate Blanchard Co-Founder & Chief Operating Officer
Marcie Glicksman Ph.D Chief Scientific Officer
Michael Fang MD Chief Medical Officer

3 Former Executives

You’re viewing 4 of 7 executives. Get the full list »

Orig3n Board Members (3)

Name Representing Role Since Contact
Info
Angela Ruggiero Self Board Member 000 0000
Byron Smith Mountain Group Partners Board Member 000 0000
Justin Xiang Ph.D Syno Capital Board Member 000 0000